Clinical trials: Fibrotic Interstitial Lung Disease, open to volunteers
Fibrotic Interstitial Lung Disease
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
The investigators plan to conduct a study to find out if giving portable oxygen therapy (during physical activity) to patients with interstitial lung disease will improve quality of life, exercise tolerance, shortness of breath…
- Trial name
- NCT06053164
- Testing
- Exertional Oxygen, Education and Support
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of Alberta
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Fibrotic Interstitial Lung Disease, IPF and PPF
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data…
- Conditions
- Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
- Trial name
- RESPOND-ILD (NCT07673237)
- Testing
- Spirometer, Oximeter, Scale
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Fibrotic Interstitial Lung Disease
Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Disease
The goal of this clinical trial is to learn whether artificial intelligence AI-enhanced remote monitoring (AIRM) is feasible, safe and acceptable for adults with fibrotic interstitial lung disease (fILD).
- Trial name
- AIRMILD (NCT07844915)
- Testing
- AIRM v1.0 AI-Enhanced Remote Monitoring
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- King's College London
Interstitial Lung Disease, Fibrotic Lung Disease
Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease
Patients with fibrotic insterstitial lung disease (ILD) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study.
- Conditions
- Interstitial Lung Disease, Fibrotic Lung Disease, Self Efficacy, Self-management
- Trial name
- NCT06027333
- Testing
- Inpatient rehabilitation (BRZ) or regular outpatient consultations (Insel), Blended patient education and self-management programme (PESM)
- Where
- 2 sites in Switzerland
- Volunteers
- 80 people
- Sponsor
- Berner Reha Zentrum AG
Fibrotic Interstitial Lung Disease
Mechanistic 129 Xe MRI Study to Assess Therapeutic Response in Fibrotic Interstitial Lung Disease
The goal of this observational study is to better understand how treatment affects the lungs of adults (ages 18-80) with fibrotic interstitial lung diseases.
- Trial name
- MASTER-ILD (NCT07786090)
- Testing
- Hyperpolarized 129Xe MRI
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Dr. Grace Parraga
Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF)
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung…
- Conditions
- Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- Trial name
- NCT07466420
- Testing
- Quercetin (dietary supplement), Usual treatment
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- Katerina M. Antoniou
Fibrotic Interstitial Lung Disease
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early antifibrotic therapy for f-ILD
- Trial name
- NCT07141810
- Testing
- Antifibrotic drugs (nidanib or pirfenidone)
- Volunteers
- 104 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Chronic Obstructive Pulmonary Disease, Bronchiectasis
Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)
Background: Some health conditions make breathing difficult and uncomfortable. When this happens every day, it is called chronic breathlessness.
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchiectasis, Interstitial Lung Disease, Lung Cancer
- Trial name
- SELF-BREATHE (NCT06326957)
- Testing
- SELF-BREATHE
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- King's College Hospital NHS Trust
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Fibrotic Interstitial Lungs Diseases
Physical Activity and Fibrosing Interstitial Lung Disease
Fibrotic interstitial lungs diseases (ILD) are a group of chronic and rare diseases characterized by an altered blood oxygenation in the lung, leading to dyspnea and physical limitation.
- Trial name
- AP-PID (NCT06182748)
- Testing
- Training on eccentric ergocycle, Training on concentric ergocycle
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris